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Background: The aim of this study was to address the effect of pure eicosapentaenoic acid(EPA) on peri-procedual(Type IVa) myocardial 
infarction(MI) after elective percutaneous coronary intervention(PCI).
methods, results: In this retrospective study, of the 180 consecutive patients with stable angina pectoris (SAP) who underwent de novo 
successful stent implantation in the native coronary artery, data from 165 patients were analyzed. Patients were assigned to receive either 
1800mg of EPA daily with statin (EPA group, n=82) or statin only (controls, n=83). To minimize the effects of selection bias for EPA administration, 
a propensity-adjusted analysis was conducted in each analysis. Peri-procedural creatine kinase-MB isoform (CK-MB) and troponin-T (TnT) were 
measured at baseline and at 18 h after PCI. Type IVa MI was defined as a post-procedural increase of TnT>3 times above the upper normal limit. The 
post-procedural index of microcirculatory resistance (IMR) values was calculated in 30 patients of the EPA group and in 32 patients of the control 
group. Changes from baseline for TnT(0.0 [0.0,0.5] vs 0.0 [0.0 , 1.4], p=0.01) were significantly lower in the EPA group compared to the control 
group. On propensity-adjusted multivariate logistic model, EPA administration (OR; 0.08, 95%CI; 0.01 - 0.50, p=0.01), low kidney function (OR; 9.93, 
95%CI; 1.65 - 59.7, p=0.01), and the presence of slow flow (OR; 6.79, 95%CI; 1.06 - 43.5, p=0.04), were significantly and independently associated 
with type IVa MI. The post procedural IMR values were significantly lower in theEPA group (19.8 [6.4, 51.1] vs 27.8[8.2, 89.3], p=0.003) compared 
to the control group even after adjustment of propensity score.
conclusions: Pre-treatmentwith EPA in addition to statins significantly reduced the incidence of type IVa MI compared to those only with statins, 
which might attribute to the effect of EPA on reducing microvascular dysfunction induced by PCI.
